Proteomic approach to studying Parkinson's disease

被引:28
|
作者
Zhang, J [1 ]
Goodlett, DR
机构
[1] Univ Washington, Seattle, WA 98195 USA
[2] Inst Syst Biol, Seattle, WA USA
关键词
Parkinson's disease; alpha-synuclein; Lewy body; proteomics;
D O I
10.1385/MN:29:3:271
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease is a common age-related neurodegenerative disease characterized pathologically by a loss of dopaminergic neurons in the substantia nigra with resultant depletion of striatal dopamine and presence of Lewy bodies in the remaining neurons. The Lewy body contains numerous functional and structural proteins, including alpha-synuclein and ubiquitin; aggregation of alpha-synuclein is thought to be important in Lewy body formation as well as neurodegeneration, although the detailed mechanisms remain to be defined. Increasing evidence has suggested that mitochondrial dysfunction, increased oxidative stress, and dysfunction of the ubiquitin-proteasome system may be involved in alpha-synuclein aggregation, Lewy body formation, and neurodegeneration. However, how these processes are related to each other is not fully understood, given that there are Parkinsonian animal models as well as human diseases with significant nigral neurodegeneration regardless of whether Lewy bodies form or not. This review summarizes the current related research fields and proposes a proteomic approach to investigate the mechanisms that may dictate alpha-synuclein aggregation, Lewy body formation, and neurodegeneration.
引用
收藏
页码:271 / 288
页数:18
相关论文
共 50 条
  • [41] Proteomic Signatures Associated with Genetic and Clinical Subtypes of Parkinson's Disease
    Lai, Mei-Yu
    Palanisamy, Divya
    Benitez, Bruno
    NEUROLOGY, 2023, 100 (17)
  • [42] Proteomic analysis of proteins related to microglial activation in Parkinson's disease
    McLaughlin, P
    GERONTOLOGIST, 2005, 45 : 54 - 54
  • [43] PROTEOMIC QUANTIFICATION OF THE S-NITROSYLATED PROTEINS IN PARKINSON DISEASE PARADIGMS
    Gu, Z.
    Meng, F.
    Wei, F.
    Cui, J.
    Liu, S.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 119 - 119
  • [44] Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery
    Mandel, Silvia
    Amit, Tamar
    Kalfon, Limor
    Youdim, Moussa B. H.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (09) : 1225 - 1240
  • [45] The Human Hippocampus in Parkinson's Disease: An Integrative Stereological and Proteomic Study
    Villar-Conde, Sandra
    Astillero-Lopez, Veronica
    Gonzalez-Rodriguez, Melania
    Villanueva-Anguita, Patricia
    Saiz-Sanchez, Daniel
    Martinez-Marcos, Alino
    Flores-Cuadrado, Alicia
    Ubeda-Banon, Isabel
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 (03) : 1345 - 1365
  • [46] Proteomic and Targeted Metabolomic Studies on a Silkworm Model of Parkinson's Disease
    Zhu, Feifei
    Chen, Han
    Han, Jinying
    Zhou, Weiwei
    Tang, Qi
    Yu, Qian
    Ma, Shangshang
    Liu, Xiaoyong
    Huo, Shuhao
    Chen, Keping
    JOURNAL OF PROTEOME RESEARCH, 2022, 21 (09) : 2114 - 2123
  • [47] An integrated proteomic approach to studying glomerular nephrotoxicity
    Cutler, P
    Bell, DJ
    Birrell, HC
    Connelly, JC
    Connor, SC
    Holmes, E
    Mitchell, BC
    Monté, SY
    Neville, BA
    Pickford, R
    Polley, S
    Schneider, K
    Skehel, JM
    ELECTROPHORESIS, 1999, 20 (18) : 3647 - 3658
  • [48] Genomic and proteomic biomarkers for Parkinson disease
    Gasser, Thomas
    NEUROLOGY, 2009, 72 : S27 - S31
  • [49] Studying the System-Level Involvement of MicroRNAs in Parkinson's Disease
    Chatterjee, Paulami
    Bhattacharyya, Malay
    Bandyopadhyay, Sanghamitra
    Roy, Debjani
    PLOS ONE, 2014, 9 (04):
  • [50] Intrepidly studying deep brain stimulation in patients with Parkinson's disease
    Deuschl, Gunther
    Krack, Paul
    LANCET NEUROLOGY, 2020, 19 (06): : 472 - 473